Immune System & Diseases - Dr. Fleming interviews Dr. Steinman Promo

You are invited to a special webcast interview:

Dr. Lawrence Steinman

From Big Hammers to Lasers: 

Lessons being learned from targeting the immune system to reverse or prevent disease


Interview by Dr. Alexander Fleming


Friday, March 23, 2018

        11 a.m. to Noon EDT


Development of immunotherapies has revolutionized medical care over the past 4 decades and promises to be increasingly important for not only autoimmune disorders but for oncology and gene therapies.  Dr. Larry Steinman, Professor of Neurology, Neurological Sciences and Pediatrics at Stanford University, and Chair of the Stanford Program in Immunology from 2001 to 2011, has been a major figure in this multi-faceted field, as researcher, entrepreneur and advisor.  Larry led efforts that resulted in important therapies for multiple diseases, including Tysabri, approvedfor multiple sclerosis (MS) and Crohn’sdisease. Dr. Steinman holds 44 patents.


His far-ranging accomplishments in basic and clinical research have been frequently honored, including the John M. Dystel Prize, the Javits Neuroscience Investigator Award twice from the National Institute of Neurological Disorders and Stroke, the Charcot Prize in MS research, the Cerami Prize in Translational Medicine, and memberships in the National Academy of Sciences, and the National Academy of Medicine.


His current interests include what provokes relapses and remissions in MS, a treatment he developed now in the clinic for Huntington’s disease, guardian molecules in the brain, which activate regulatory B cells to protect against inflammation, and a focus of the interview, an antigen specific treatment for type 1 diabetes (expected to enter a pivotal clinical trial this year).


Larry Steinman is a gifted speaker and teacher.  Don’t miss this opportunity to hear important insights about how the field of immunotherapy has evolved and where it is going.


Interviewer G. Alexander (“Zan”) Fleming, M.D., is an endocrinologist trained at Emory, Vanderbilt and NIH who led landmark regulatory reviews at the FDA, which led to the approval of the first statin, insulin analog, metformin, PPAR-agonist and growth hormone for non-growth hormone indications.  


Zan, founder of the strategic regulatory and clinical advisory firm Kinexum, will be chairing the closing panel at the GTC Bio Diabetes Summit in Boston April 9-11, 2018.


Join the call at: or dial in number:

888-601-3595 (alternate number: 304-362-9327) No PIN needed.